Concepts (160)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tomography, Optical Coherence | 19 | 2025 | 223 | 2.550 |
Why?
|
| Wet Macular Degeneration | 4 | 2025 | 26 | 2.180 |
Why?
|
| Visual Acuity | 15 | 2025 | 125 | 2.120 |
Why?
|
| Macular Degeneration | 6 | 2023 | 187 | 1.880 |
Why?
|
| Retinal Diseases | 4 | 2024 | 33 | 1.520 |
Why?
|
| Angiogenesis Inhibitors | 7 | 2024 | 77 | 1.470 |
Why?
|
| Macular Edema | 3 | 2024 | 24 | 1.440 |
Why?
|
| Retinal Pigment Epithelium | 4 | 2025 | 35 | 1.230 |
Why?
|
| Fluorescein Angiography | 9 | 2025 | 58 | 0.990 |
Why?
|
| Retinal Vasculitis | 2 | 2022 | 7 | 0.940 |
Why?
|
| Ranibizumab | 3 | 2022 | 20 | 0.910 |
Why?
|
| Intravitreal Injections | 8 | 2024 | 49 | 0.910 |
Why?
|
| Retinal Vein Occlusion | 1 | 2024 | 18 | 0.850 |
Why?
|
| Geographic Atrophy | 4 | 2024 | 20 | 0.830 |
Why?
|
| Hawks | 1 | 2022 | 1 | 0.780 |
Why?
|
| Retinal Dystrophies | 1 | 2021 | 4 | 0.750 |
Why?
|
| Peripherins | 1 | 2021 | 14 | 0.740 |
Why?
|
| Retina | 3 | 2024 | 124 | 0.710 |
Why?
|
| Cysts | 2 | 2013 | 41 | 0.680 |
Why?
|
| Endotamponade | 1 | 2020 | 7 | 0.650 |
Why?
|
| Basement Membrane | 1 | 2020 | 25 | 0.650 |
Why?
|
| Retinal Perforations | 1 | 2020 | 8 | 0.650 |
Why?
|
| Fovea Centralis | 2 | 2023 | 17 | 0.640 |
Why?
|
| Vitrectomy | 1 | 2020 | 26 | 0.640 |
Why?
|
| Diabetic Retinopathy | 2 | 2021 | 53 | 0.640 |
Why?
|
| Vitreous Body | 3 | 2024 | 31 | 0.600 |
Why?
|
| Choroid Neoplasms | 2 | 2016 | 21 | 0.580 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2016 | 212 | 0.550 |
Why?
|
| Laser Coagulation | 3 | 2016 | 15 | 0.550 |
Why?
|
| Ectopia Lentis | 1 | 2014 | 1 | 0.460 |
Why?
|
| Humans | 33 | 2025 | 63292 | 0.460 |
Why?
|
| Marfan Syndrome | 1 | 2014 | 18 | 0.450 |
Why?
|
| Glomerulonephritis, IGA | 1 | 2014 | 8 | 0.450 |
Why?
|
| Nocardia | 1 | 2014 | 1 | 0.440 |
Why?
|
| Nocardia Infections | 1 | 2014 | 3 | 0.440 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2014 | 46 | 0.440 |
Why?
|
| Eye Infections, Bacterial | 1 | 2014 | 6 | 0.440 |
Why?
|
| Retinal Drusen | 1 | 2014 | 16 | 0.440 |
Why?
|
| Endophthalmitis | 1 | 2014 | 12 | 0.440 |
Why?
|
| Lasers | 1 | 2014 | 36 | 0.430 |
Why?
|
| Eye Injuries | 1 | 2014 | 14 | 0.430 |
Why?
|
| Radiosurgery | 1 | 2014 | 62 | 0.430 |
Why?
|
| Blindness | 1 | 2014 | 41 | 0.430 |
Why?
|
| Muscle Cramp | 1 | 2013 | 2 | 0.410 |
Why?
|
| POEMS Syndrome | 1 | 2013 | 2 | 0.410 |
Why?
|
| Femoral Neoplasms | 1 | 2013 | 5 | 0.410 |
Why?
|
| Conjunctival Diseases | 1 | 2013 | 2 | 0.410 |
Why?
|
| Strabismus | 1 | 2013 | 2 | 0.410 |
Why?
|
| Pigment Epithelium of Eye | 2 | 2015 | 12 | 0.400 |
Why?
|
| Follow-Up Studies | 5 | 2025 | 2460 | 0.390 |
Why?
|
| Fundus Oculi | 2 | 2025 | 22 | 0.360 |
Why?
|
| Male | 17 | 2025 | 29814 | 0.340 |
Why?
|
| Bevacizumab | 3 | 2024 | 59 | 0.340 |
Why?
|
| Choroidal Neovascularization | 2 | 2023 | 28 | 0.330 |
Why?
|
| Adult | 11 | 2024 | 16782 | 0.300 |
Why?
|
| Aged | 9 | 2025 | 14390 | 0.300 |
Why?
|
| Female | 17 | 2025 | 32787 | 0.300 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2022 | 33 | 0.290 |
Why?
|
| Multiple Myeloma | 1 | 2013 | 349 | 0.280 |
Why?
|
| Eye Diseases | 1 | 2008 | 36 | 0.280 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2022 | 489 | 0.250 |
Why?
|
| Postoperative Complications | 1 | 2013 | 1303 | 0.240 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 1199 | 0.240 |
Why?
|
| Atrophy | 1 | 2025 | 83 | 0.230 |
Why?
|
| Aged, 80 and over | 5 | 2025 | 5448 | 0.220 |
Why?
|
| Subretinal Fluid | 2 | 2022 | 3 | 0.220 |
Why?
|
| Amyl Nitrite | 1 | 2024 | 3 | 0.220 |
Why?
|
| Retrospective Studies | 5 | 2025 | 6629 | 0.220 |
Why?
|
| Aptamers, Nucleotide | 1 | 2023 | 22 | 0.210 |
Why?
|
| Complement Inactivating Agents | 1 | 2023 | 14 | 0.210 |
Why?
|
| Treatment Outcome | 4 | 2024 | 5651 | 0.200 |
Why?
|
| Polyethylene Glycols | 1 | 2023 | 168 | 0.190 |
Why?
|
| Choroid Diseases | 1 | 2021 | 5 | 0.190 |
Why?
|
| Middle Aged | 8 | 2024 | 17549 | 0.180 |
Why?
|
| Pedigree | 1 | 2021 | 193 | 0.180 |
Why?
|
| Uveitis | 1 | 2021 | 34 | 0.170 |
Why?
|
| Prone Position | 1 | 2020 | 28 | 0.160 |
Why?
|
| Postoperative Period | 1 | 2020 | 138 | 0.160 |
Why?
|
| Double-Blind Method | 3 | 2024 | 738 | 0.140 |
Why?
|
| Osteoma | 1 | 2016 | 1 | 0.130 |
Why?
|
| Posterior Eye Segment | 1 | 2016 | 1 | 0.130 |
Why?
|
| Eye Infections, Viral | 1 | 2016 | 3 | 0.120 |
Why?
|
| Coxsackievirus Infections | 1 | 2016 | 12 | 0.120 |
Why?
|
| Retinal Detachment | 1 | 2016 | 18 | 0.120 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2014 | 1618 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2021 | 233 | 0.120 |
Why?
|
| Varicose Veins | 1 | 2015 | 7 | 0.120 |
Why?
|
| Albinism, Oculocutaneous | 1 | 2015 | 1 | 0.120 |
Why?
|
| Iris Diseases | 1 | 2015 | 2 | 0.120 |
Why?
|
| Lenses, Intraocular | 1 | 2015 | 6 | 0.120 |
Why?
|
| Venous Pressure | 1 | 2015 | 2 | 0.120 |
Why?
|
| Valsalva Maneuver | 1 | 2015 | 11 | 0.120 |
Why?
|
| Retinal Hemorrhage | 1 | 2015 | 7 | 0.120 |
Why?
|
| Retinal Neoplasms | 1 | 2015 | 18 | 0.120 |
Why?
|
| Choroid | 1 | 2015 | 26 | 0.120 |
Why?
|
| Macula Lutea | 1 | 2015 | 22 | 0.120 |
Why?
|
| Central Serous Chorioretinopathy | 1 | 2014 | 3 | 0.110 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2014 | 8 | 0.110 |
Why?
|
| Lens, Crystalline | 1 | 2014 | 16 | 0.110 |
Why?
|
| Tuberous Sclerosis | 1 | 2014 | 11 | 0.110 |
Why?
|
| Global Health | 1 | 2016 | 183 | 0.110 |
Why?
|
| Hypopigmentation | 1 | 2015 | 17 | 0.110 |
Why?
|
| Radiotherapy Dosage | 1 | 2014 | 84 | 0.110 |
Why?
|
| Remission Induction | 1 | 2014 | 148 | 0.110 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2014 | 10 | 0.110 |
Why?
|
| Indoles | 1 | 2014 | 110 | 0.110 |
Why?
|
| Mycophenolic Acid | 1 | 2014 | 68 | 0.110 |
Why?
|
| Biopsy, Needle | 1 | 2014 | 138 | 0.110 |
Why?
|
| Diagnosis, Differential | 2 | 2015 | 972 | 0.110 |
Why?
|
| Cerebrospinal Fluid Pressure | 1 | 2013 | 5 | 0.100 |
Why?
|
| Exercise Test | 1 | 2015 | 252 | 0.100 |
Why?
|
| Phlebography | 1 | 2013 | 44 | 0.100 |
Why?
|
| Papilledema | 1 | 2013 | 10 | 0.100 |
Why?
|
| Mutation | 1 | 2021 | 2607 | 0.100 |
Why?
|
| Neoplasm Staging | 1 | 2014 | 502 | 0.100 |
Why?
|
| Child | 3 | 2014 | 4522 | 0.100 |
Why?
|
| Anti-Infective Agents | 1 | 2014 | 150 | 0.100 |
Why?
|
| Incidence | 1 | 2016 | 1375 | 0.090 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 893 | 0.090 |
Why?
|
| Adenocarcinoma | 1 | 2015 | 342 | 0.090 |
Why?
|
| Vision Disorders | 3 | 2016 | 64 | 0.080 |
Why?
|
| Uveal Neoplasms | 1 | 2009 | 50 | 0.080 |
Why?
|
| Supine Position | 1 | 2008 | 32 | 0.070 |
Why?
|
| Risk Assessment | 1 | 2014 | 2071 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2009 | 297 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 2571 | 0.060 |
Why?
|
| Melanoma | 1 | 2009 | 331 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2023 | 3285 | 0.060 |
Why?
|
| Indocyanine Green | 2 | 2015 | 10 | 0.060 |
Why?
|
| Coloring Agents | 2 | 2015 | 54 | 0.060 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2024 | 34 | 0.060 |
Why?
|
| Animals | 1 | 2022 | 20631 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 2164 | 0.050 |
Why?
|
| Organic Chemicals | 1 | 2023 | 23 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2024 | 860 | 0.050 |
Why?
|
| Patient Selection | 1 | 2024 | 488 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 453 | 0.040 |
Why?
|
| Adolescent | 3 | 2016 | 6238 | 0.040 |
Why?
|
| Time Factors | 1 | 2024 | 3759 | 0.030 |
Why?
|
| Retinitis | 1 | 2016 | 6 | 0.030 |
Why?
|
| Multimodal Imaging | 1 | 2016 | 67 | 0.030 |
Why?
|
| Miosis | 1 | 2015 | 2 | 0.030 |
Why?
|
| Melanins | 1 | 2015 | 24 | 0.030 |
Why?
|
| Prednisolone | 1 | 2014 | 8 | 0.030 |
Why?
|
| Ketorolac | 1 | 2014 | 13 | 0.030 |
Why?
|
| Nonprescription Drugs | 1 | 2014 | 17 | 0.030 |
Why?
|
| Acne Vulgaris | 1 | 2014 | 24 | 0.030 |
Why?
|
| Headache | 1 | 2014 | 58 | 0.030 |
Why?
|
| Inflammation | 1 | 2021 | 1146 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2014 | 463 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2014 | 188 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 205 | 0.020 |
Why?
|
| Young Adult | 2 | 2016 | 4683 | 0.020 |
Why?
|
| Phenotype | 1 | 2016 | 1200 | 0.020 |
Why?
|
| Eye Enucleation | 1 | 2009 | 9 | 0.020 |
Why?
|
| Cryotherapy | 1 | 2009 | 16 | 0.020 |
Why?
|
| Hyperthermia, Induced | 1 | 2009 | 21 | 0.020 |
Why?
|
| Brachytherapy | 1 | 2009 | 37 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2009 | 1988 | 0.010 |
Why?
|
| Risk Factors | 1 | 2009 | 5338 | 0.010 |
Why?
|